Related Experiment Video
Updated: Jun 13, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Bile acid sequestrants for lipid and glucose control
Bart Staels1, Yehuda Handelsman, Vivian Fonseca
1Institut Pasteur de Lille, 1 rue Calmette BP245, 59019, Lille cedex, France. Bart.Staels@pasteur-lille.fr
Current Diabetes Reports
|April 29, 2010
Summary
Bile acids regulate metabolism and act as signaling molecules. Bile acid sequestrants improve lipid and glucose levels by modulating these pathways, offering potential benefits for type 2 diabetes.
Area of Science:
- Endocrinology
- Metabolic Research
- Pharmacology
Background:
- Bile acids, produced in the liver, traditionally regulate nutrient absorption and cholesterol homeostasis.
- Emerging research highlights bile acids as signaling molecules activating farnesoid X receptor (FXR) and TGR5 pathways.
- These pathways are crucial for integrating lipid and glucose metabolism.
Purpose of the Study:
- To examine the mechanisms of bile acid-mediated FXR and TGR5 signaling.
- To explore the implications for bile acid sequestrant effects on lipid and glucose metabolism.
- To understand the role of these pathways in type 2 diabetes mellitus (T2DM).
Main Methods:
- Review of literature on bile acid signaling and metabolic regulation.
- Analysis of FXR and TGR5 pathway activation by bile acids.
- Examination of pharmacological data on bile acid sequestrants.
Main Results:
- Bile acids activate FXR and TGR5, influencing lipid and glucose metabolism.
- Bile acid sequestrants interrupt bile acid homeostasis, lowering LDL cholesterol.
- Bile acid sequestrants demonstrate glucose-lowering effects and improve glycemic control in T2DM.
Conclusions:
- Bile acid-mediated FXR and TGR5 signaling are key regulators of metabolic processes.
- Bile acid sequestrants leverage these pathways to improve lipid and glucose profiles.
- Targeting bile acid signaling offers therapeutic potential for T2DM and hypercholesterolemia.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...